{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:17:11Z","timestamp":1791037031990,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s10549-010-1137-z","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T02:49:14Z","timestamp":1285642154000},"page":"233-241","source":"Crossref","is-referenced-by-count":51,"title":["Risk of second breast cancer according to estrogen receptor status and family history"],"prefix":"10.1007","volume":"127","author":[{"given":"Christine","family":"Bouchardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Fioretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre O.","family":"Chappuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Neyroud-Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Vinh-Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Vlastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rapiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"issue":"10","key":"1137_CR1","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8(10):855\u2013861","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1137_CR2","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials (1998) Lancet 351 (9114): 1451\u20131467","DOI":"10.1016\/S0140-6736(97)11423-4"},{"issue":"13","key":"1137_CR3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/jnci\/93.13.1008","volume":"93","author":"CI Li","year":"2001","unstructured":"Li CI, Malone KE, Weiss NS, Daling JR (2001) Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 93(13):1008\u20131013","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1137_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6600746","volume":"88","author":"R Kaas","year":"2003","unstructured":"Kaas R, Peterse JL, Hart AA, Voogd AC, Rutgers EJ, Van Leeuwen FE (2003) The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. Br J Cancer 88(5):707\u2013710","journal-title":"Br J Cancer"},{"issue":"7","key":"1137_CR5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djh097","volume":"96","author":"SM Swain","year":"2004","unstructured":"Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N (2004) Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 96(7):516\u2013523","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"1137_CR6","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1200\/JCO.2005.04.076","volume":"23","author":"G Arpino","year":"2005","unstructured":"Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK (2005) Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 23(21):4687\u20134694","journal-title":"J Clin Oncol"},{"issue":"6","key":"1137_CR7","doi-asserted-by":"crossref","first-page":"R1153","DOI":"10.1186\/bcr1342","volume":"7","author":"LJ Esserman","year":"2005","unstructured":"Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM (2005) Tamoxifen may prevent both ER+ and ER\u2212 breast cancers and select for ER\u2212 carcinogenesis: an alternative hypothesis. Breast Cancer Res 7(6):R1153\u2013R1158","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1137_CR8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1075-122X.2005.21579.x","volume":"11","author":"A Stark","year":"2005","unstructured":"Stark A, Lu M, Mackowiak P, Linden M (2005) Concordance of the hormone receptors and correlation of HER-2\/neu overexpression of the metachronous cancers of contralateral breasts. Breast J 11(3):183\u2013187","journal-title":"Breast J"},{"issue":"17","key":"1137_CR9","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1158\/0008-5472.CAN-09-1355","volume":"69","author":"CI Li","year":"2009","unstructured":"Li CI, Daling JR, Porter PL, Tang MT, Malone KE (2009) Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res 69(17):6865\u20136870","journal-title":"Cancer Res"},{"issue":"5","key":"1137_CR10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.ede.0000072105.39021.6d","volume":"14","author":"JL Bernstein","year":"2003","unstructured":"Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14(5):552\u2013558","journal-title":"Epidemiology"},{"issue":"6","key":"1137_CR11","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/1055-9965.EPI-05-0070","volume":"14","author":"JN Weitzel","year":"2005","unstructured":"Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA (2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 14(6):1534\u20131538","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1137_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1010665603732","volume":"67","author":"Y Chen","year":"2001","unstructured":"Chen Y, Semenciw R, Kliewer E, Shi Y, Mao Y (2001) Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada. Breast Cancer Res Treat 67(1):35\u201340","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1137_CR13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.bjc.6601042","volume":"89","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Porter PL, Daling JR (2003) Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89(3):513\u2013518","journal-title":"Br J Cancer"},{"issue":"2","key":"1137_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9445-z","volume":"105","author":"J Ji","year":"2007","unstructured":"Ji J, Hemminki K (2007) Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat 105(2):229\u2013236","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1137_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0959-8049(98)00378-5","volume":"35","author":"K Hemminki","year":"1999","unstructured":"Hemminki K, Vaittinen P (1999) Familial risks in second primary breast cancer based on a family cancer database. Eur J Cancer 35(3):455\u2013458","journal-title":"Eur J Cancer"},{"issue":"2","key":"1137_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","volume":"105","author":"A Trentham-Dietz","year":"2007","unstructured":"Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM (2007) Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 105(2):195\u2013207","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"1137_CR17","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.ejca.2007.08.005","volume":"43","author":"WJ Louwman","year":"2007","unstructured":"Louwman WJ, Vulto JC, Verhoeven RH, Nieuwenhuijzen GA, Coebergh JW, Voogd AC (2007) Clinical epidemiology of breast cancer in the elderly. Eur J Cancer 43(15):2242\u20132252","journal-title":"Eur J Cancer"},{"issue":"2","key":"1137_CR18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oxfordjournals.aje.a114971","volume":"128","author":"PL Horn","year":"1988","unstructured":"Horn PL, Thompson WD (1988) Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 128(2):309\u2013323","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1137_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1677\/erc.1.01118","volume":"13","author":"SM Dougherty","year":"2006","unstructured":"Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM (2006) Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13(1):113\u2013134","journal-title":"Endocr Relat Cancer"},{"issue":"1\u20132","key":"1137_CR20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mce.2009.01.021","volume":"305","author":"MM Ivanova","year":"2009","unstructured":"Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM (2009) Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol 305(1\u20132):12\u201321","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"1137_CR21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(06)70693-3","volume":"7","author":"S Dubey","year":"2006","unstructured":"Dubey S, Siegfried JM, Traynor AM (2006) Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 7(5):416\u2013424","journal-title":"Lancet Oncol"},{"issue":"14","key":"1137_CR22","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1158\/1078-0432.CCR-07-1950","volume":"14","author":"H Niikawa","year":"2008","unstructured":"Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T, Sasano H (2008) Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14(14):4417\u20134426","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1137_CR23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-04-1872","volume":"65","author":"LP Stabile","year":"2005","unstructured":"Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65(4):1459\u20131470","journal-title":"Cancer Res"},{"issue":"15","key":"1137_CR24","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jnci\/djp181","volume":"101","author":"AW Kurian","year":"2009","unstructured":"Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101(15):1058\u20131065","journal-title":"J Natl Cancer Inst"},{"key":"1137_CR25","unstructured":"Bouchardy C (2007) Switzerland, Geneva. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) Cancer incidence in five continents vol. IX. International Agency for Research on Cancer, Lyon, pp 369\u2013370"},{"key":"1137_CR26","volume-title":"ICD-O International classification of diseases for oncology","year":"2000","unstructured":"Fritz A, Percy C, A A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds) (2000) ICD-O International classification of diseases for oncology. World Health Organization, Geneva"},{"key":"1137_CR27","volume-title":"Person-Years (PYRS). A Fortran program for cohort study analysis. IARC Internal Report no. 89\/006","author":"MP Coleman","year":"1989","unstructured":"Coleman MP, Hermon C, Douglas A (1989) Person-Years (PYRS). A Fortran program for cohort study analysis. IARC Internal Report no. 89\/006. International Agency for Research on Cancer, Lyon"},{"issue":"2","key":"1137_CR28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/annonc\/mdh072","volume":"15","author":"HM Verkooijen","year":"2004","unstructured":"Verkooijen HM, Fioretta G, Chappuis PO, Vlastos G, Sappino AP, Benhamou S, Bouchardy C (2004) Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results. Ann Oncol 15(2):350\u2013353","journal-title":"Ann Oncol"},{"issue":"35","key":"1137_CR29","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechthold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887\u20135892","journal-title":"J Clin Oncol"},{"issue":"1","key":"1137_CR30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-009-0469-z","volume":"120","author":"M Brown","year":"2010","unstructured":"Brown M, Bauer K, Pare M (2010) Tumor marker phenotype concordance in second primary breast cancer, California, 1999\u20132004. Breast Cancer Res Treat 120(1):217\u2013227","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"1137_CR31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jnci\/91.23.2020","volume":"91","author":"PL Porter","year":"1999","unstructured":"Porter PL, El Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020\u20132028","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1137_CR32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/1097-0142(19800115)45:2<349::AID-CNCR2820450226>3.0.CO;2-P","volume":"45","author":"ER Fisher","year":"1980","unstructured":"Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B (1980) Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45(2):349\u2013353","journal-title":"Cancer"},{"issue":"14","key":"1137_CR33","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","volume":"295","author":"DA Berry","year":"2006","unstructured":"Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658\u20131667","journal-title":"JAMA"},{"issue":"7","key":"1137_CR34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1200\/JCO.1988.6.7.1076","volume":"6","author":"B Fisher","year":"1988","unstructured":"Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076\u20131087","journal-title":"J Clin Oncol"},{"issue":"7","key":"1137_CR35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133\u20131144","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1137-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1137-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T23:29:00Z","timestamp":1559690940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1137-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1137-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]}}}